<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907825</url>
  </required_header>
  <id_info>
    <org_study_id>00000850</org_study_id>
    <nct_id>NCT04907825</nct_id>
  </id_info>
  <brief_title>A Trial of Pharmacist Management of Oral Anticoagulation THerapy Versus Enhanced Usual CARe in the communitY for AF</brief_title>
  <acronym>APOTHECARYAF</acronym>
  <official_title>A Trial of Pharmacist Management of Oral Anticoagulation THerapy Versus Enhanced Usual CARe in the communitY for AF (APOTHECARY AF Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, cluster-randomized controlled trial of 380 participants&#xD;
      (aged 65 years or older, with additional stroke risk factors and 'actionable' undertreated&#xD;
      AF) from a total of 38 retail and outpatient community pharmacies. Participants will be&#xD;
      randomized (by pharmacy) to either to an intervention arm of pharmacist-led OAC management&#xD;
      versus an enhanced usual care arm, wherein physicians receive notification of 'actionable' AF&#xD;
      and patients are advised to schedule a physician clinic visit. The primary objective will be&#xD;
      to determine the difference in proportion of patients with 'actionable AF' receiving&#xD;
      guideline concordant OAC therapy at 3 months in those randomized to intervention arm versus&#xD;
      control arm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral anticoagulation therapy for stroke prevention in AF is safe and effective but&#xD;
      under-utilized. Optimal delivery of existing therapies would prevent AF-related stroke.&#xD;
      Therefore alternative strategies to increase adherence to current guidelines for OAC use for&#xD;
      AF stroke prevention should be explored.&#xD;
&#xD;
      Accumulating data indicate that pharmacist-led or pharmacist-collaborative care in&#xD;
      cardiovascular disease monitoring, risk factor control, and medication optimization leads to&#xD;
      greater adherence to guideline-directed targets and improved outcomes.&#xD;
&#xD;
      In this prospective, open-label, cluster-randomized controlled trial the investigators intend&#xD;
      to enroll 380 participants (aged 65 years or older, with additional stroke risk factors and&#xD;
      'actionable' undertreated AF) from a total of 38 retail and outpatient community pharmacies&#xD;
      in Los Angeles. Participants will be randomized (by pharmacy) to either to an intervention&#xD;
      arm of pharmacist-led OAC management versus an enhanced usual care arm, wherein physicians&#xD;
      receive notification of 'actionable' AF and patients are advised to schedule a physician&#xD;
      clinic visit. The primary objective will be to determine the difference in proportion of&#xD;
      patients with 'actionable AF' receiving guideline concordant OAC therapy at 3 months in those&#xD;
      randomized to intervention arm versus control arm. Secondary outcomes include: patient&#xD;
      satisfaction with pharmacist services (at 3 months), pharmacists' perspective on study&#xD;
      implementation (at study end), and OAC adherence (at 1 year). In an exploratory aim, the&#xD;
      investigators will assess healthcare utilization and clinical outcomes at 1 year.&#xD;
&#xD;
      This research will generate new knowledge on an innovative, and potentially sustainable&#xD;
      stroke prevention strategy to increase evidence-based use of OAC therapy in patients with AF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, open-label, cluster-randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal OAC Therapy</measure>
    <time_frame>At 3 months</time_frame>
    <description>To determine the difference in proportion of patients with 'actionable AF' receiving optimal OAC therapy at 3 months in those randomized to intervention arm versus control arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>'Actionable' AF Prevalence</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To determine the prevalence of patients with 'actionable AF'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence (NOAC)</measure>
    <time_frame>At 12 months</time_frame>
    <description>To assess OAC adherence (i.e. proportion of days covered (PDC) for NOACS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence (Warfarin)</measure>
    <time_frame>At 12 months</time_frame>
    <description>To assess OAC adherence (i.e. time in the therapeutic range (TTR) for warfarin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction with Pharmacist Services</measure>
    <time_frame>At 3 months</time_frame>
    <description>To assess patient satisfaction with pharmacist services using 22-item questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative Review of Program Implementation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To perform a qualitative review of program implementation by surveying pharmacists about their experiences with 11-item questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Utilization</measure>
    <time_frame>At 12 months</time_frame>
    <description>To assess healthcare utilization (i.e. the number of physician visits, specialist visits, ED visits, and hospitalizations)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Pharmacist Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacist to prescribe/monitor/manage oral anticoagulation therapy for atrial fibrillation stroke prophylaxis (under collaborative practice agreement with participants primary care provider) in accordance with ACC/AHA/HRS Guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced Usual Care Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pharmacist to notify primary care provider that patient has 'actionable' atrial fibrillation and provide current medication list.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral anticoagulant</intervention_name>
    <description>Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with ACC/AHA/HRS Guidelines</description>
    <arm_group_label>Enhanced Usual Care Control Arm</arm_group_label>
    <arm_group_label>Pharmacist Intervention Arm</arm_group_label>
    <other_name>warfarin</other_name>
    <other_name>novel oral anticoagulants</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 65 years&#xD;
&#xD;
          2. Men (CHADS-VASc score ≥2) AND Women (CHADS-VASc score ≥3)&#xD;
&#xD;
          3. AF and not on OAC therapy but eligible&#xD;
&#xD;
          4. AF and on sub-optimal or inappropriate OAC therapy&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. AF on optimal OAC therapy&#xD;
&#xD;
          2. OAC required for other conditions (i.e. DVT/PE, PCI in prior year, left ventricular&#xD;
             thrombus, etc.)&#xD;
&#xD;
          3. Currently taking two antiplatelet agents&#xD;
&#xD;
          4. Uncontrolled hypertension (defined as SBP ≥160 mmHg x 2 BP readings measured at&#xD;
             screening)&#xD;
&#xD;
          5. End-stage renal disease (CrCl &lt;15 ml/min or dialysis)&#xD;
&#xD;
          6. Major surgery in prior month (defined as surgery requiring general anesthesia and&#xD;
             overnight inpatient hospital stay)&#xD;
&#xD;
          7. History of &quot;major bleeding&quot; in prior year (defined as overt bleeding at critical site&#xD;
             including intracranial, intraspinal, intraocular, pericardial, GI bleed, bleed&#xD;
             requiring hospitalization, bleed resulting in ≥20 g/L drop in hemoglobin or requiring&#xD;
             transfusion of ≥2 units packed cells)&#xD;
&#xD;
          8. Excess alcohol intake (≥8 alcoholic drinks/week)&#xD;
&#xD;
          9. Inability to read or understand English&#xD;
&#xD;
         10. Participants considered unreliable by the Investigator or designated pharmacy team&#xD;
             member concerning the requirements of follow-up, or those with foreshortened life&#xD;
             expectancy precluding 3-month follow-up&#xD;
&#xD;
         11. Severe cognitive impairment (≥5 errors on the Short Portable Mental Status&#xD;
             Questionnaire)&#xD;
&#xD;
         12. Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roopinder K Sandhu, MD</last_name>
    <phone>424-315-4519</phone>
    <email>roopinder.sandhu@cshs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ciantel Adair Blyler, PharmD</last_name>
    <phone>310-425-2904</phone>
    <email>ciantel.blyler@cshs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ciantel Adair Blyler, PharmD</last_name>
      <phone>310-425-2904</phone>
      <email>ciantel.blyler@cshs.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Roopinder Sandhu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Stroke</keyword>
  <keyword>Oral Anticoagulants</keyword>
  <keyword>Pharmacist Case Management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

